Merus/$MRUS
Merus shares are trading higher after interim data showed strong efficacy and durability for Petosemtamab with Pembrolizumab in a clinical study.
57 minutes ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Ticker
$MRUS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
291
ISIN
NL0011606264
Website
Merus Metrics
BasicAdvanced
$2.9B
-
-$4.14
0.95
-
Price and volume
Market cap
$2.9B
Beta
0.95
52-week high
$61.61
52-week low
$33.19
Average daily volume
875K
Financial strength
Current ratio
5.86
Quick ratio
5.337
Long term debt to equity
1.356
Total debt to equity
1.653
Management effectiveness
Return on assets (TTM)
-30.61%
Return on equity (TTM)
-58.66%
Valuation
Price to revenue (TTM)
50.889
Price to book
4.83
Price to tangible book (TTM)
4.84
Price to free cash flow (TTM)
-11.613
Growth
Revenue change (TTM)
42.77%
Earnings per share change (TTM)
50.98%
3-year revenue growth (CAGR)
1.45%
3-year earnings per share growth (CAGR)
30.42%
What the Analysts think about Merus
Analyst ratings (Buy, Hold, Sell) for Merus stock.
Merus Financial Performance
Revenues and expenses
Merus Earnings Performance
Company profitability
Merus News
AllArticlesVideos
Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
GlobeNewsWire·18 hours ago
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
GlobeNewsWire·2 weeks ago
Merus: Riding The Bispecific Wave In Oncology
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merus stock?
Merus (MRUS) has a market cap of $2.9B as of May 23, 2025.
What is the P/E ratio for Merus stock?
The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of May 23, 2025.
Does Merus stock pay dividends?
No, Merus (MRUS) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Merus dividend payment date?
Merus (MRUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Merus?
Merus (MRUS) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.